Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03128606
Recruitment Status : Completed
First Posted : April 25, 2017
Last Update Posted : April 10, 2018
Sponsor:
Information provided by (Responsible Party):
Galapagos NV

Brief Summary:

The study is a First-in-Human, Phase I, randomized, double-blind, placebo-controlled, single center study, evaluating single and multiple ascending oral doses of GLPG3067 and the combination of GLPG3067 and GLPG2222 and the combination of GLPG3067,GLPG2222 and GLPG2737 given for 14 days in healthy women of non-childbearing potential.

The purpose of the study is to evaluate the safety and tolerability of single ascending oral doses and multiple ascending oral doses of GLPG3067 given to healthy women of non-childbearing potential compared to placebo, as well as of multiple oral doses of the combination of GLPG3067/GLPG2222 compared to matching placebo for each compound and multiple oral doses of the combination of GLPG3067/GLPG2222/GLPG2737 compared to matching placebo for each compound.


Condition or disease Intervention/treatment Phase
Healthy Drug: GLPG3067 single dose Drug: Placebo single dose Drug: GLPG3067 multiple dose Drug: Placebo multiple dose Drug: GLPG3067 oral suspension Drug: GLPG3067 oral tablet Drug: GLPG3067/GLPG2222 multiple dose Drug: GLPG3067/GLPG2222 Placebo multiple dose Drug: GLPG3067/GLPG2222/GLPG2737 multiple dose Drug: GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG3067, the Combination of GLPG3067 and GLPG2222, and the Combination of GLPG3067, GLPG2222 and GLPG2737 in Healthy Female Subjects, Including a Relative Bioavailability and Food Effect Part for Single Dose of GLPG3067.
Actual Study Start Date : March 28, 2017
Actual Primary Completion Date : February 20, 2018
Actual Study Completion Date : February 20, 2018

Arm Intervention/treatment
Experimental: GLPG3067 single dose
Single dose of GLPG3067 oral suspension at up to 6 dose levels in ascending order.
Drug: GLPG3067 single dose
GLPG3067 oral suspension, single ascending doses, daily

Placebo Comparator: Placebo single dose
Single dose of Placebo oral suspension.
Drug: Placebo single dose
Placebo, oral suspension, daily

Experimental: GLPG3067 oral suspension fed 1
Single dose 1 of GLPG3067 oral suspension after a standardized breakfast.
Drug: GLPG3067 oral suspension
GLPG3067 oral suspension, single dose, daily

Experimental: GLPG3067 oral tablet fed 1
Single dose 1 of GLPG3067 oral tablet after a standardized breakfast.
Drug: GLPG3067 oral tablet
GLPG3067 oral tablet, single dose, daily

Experimental: GLPG3067 oral tablet fasted 1
Single dose 1 of GLPG3067 oral tablet after an overnight fast.
Drug: GLPG3067 oral tablet
GLPG3067 oral tablet, single dose, daily

Experimental: GLPG3067 oral tablet fed 2
Single dose 2 of GLPG3067 oral tablet after a standardized breakfast.
Drug: GLPG3067 oral tablet
GLPG3067 oral tablet, single dose, daily

Experimental: GLPG3067 oral tablet fed 2 high-fat high-calorie
Single dose 2 of GLPG3067 oral tablet after a high-fat high-calorie breakfast
Drug: GLPG3067 oral tablet
GLPG3067 oral tablet, single dose, daily

Experimental: GLPG3067 multiple dose
Multiple doses of GLPG3067 oral suspension at up to 5 dose levels in ascending order.
Drug: GLPG3067 multiple dose
GLPG3067 oral suspension, multiple ascending doses, daily for 14 days

Placebo Comparator: Placebo multiple dose
Multiple doses of Placebo oral suspension.
Drug: Placebo multiple dose
Placebo, oral suspension, daily for 14 days

Experimental: GLPG3067/GLPG2222 multiple dose
Multiple doses of GLPG3067 oral suspension combined with GLPG2222 oral tablet up to 2 dose levels in ascending order.
Drug: GLPG3067/GLPG2222 multiple dose
GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days

Placebo Comparator: GLPG3067/GLPG2222 Placebo multiple dose
Multiple doses of GLPG3067 matching placebo oral suspension combined with GLPG2222 matching placebo oral tablet.
Drug: GLPG3067/GLPG2222 Placebo multiple dose
GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days

Experimental: GLPG3067/GLPG2222/GLPG2737 multiple dose
Multiple doses of GLPG3067 oral tablet combined with GLPG2222 oral tablet and GLPG2737 oral capsule at up to 2 dose levels in ascending order.
Drug: GLPG3067/GLPG2222/GLPG2737 multiple dose
GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days

Placebo Comparator: GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose
Multiple doses of GLPG3067 matching placebo oral tablet combined with GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule.
Drug: GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose
GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days




Primary Outcome Measures :
  1. Change versus placebo in the proportion of subjects with adverse events [ Time Frame: Between screening and 14 days after the last dose ]
    To assess safety and tolerability of single ascending doses, multiple ascending doses of GLPG3067 alone, or in combination with GLPG2222, or in combination with GLPG2222 and GLPG2737 versus placebo in healthy subjects


Secondary Outcome Measures :
  1. Maximum observed plasma concentration of GLPG3067 (Cmax) given alone or in combination with GLPG2222 or in combination with GLPG2222 and GLPG2737 [ Time Frame: Between Day 1 predose and 10 days after the last dose ]
    To characterize pharmacokinetics of GLPG3067 after a single oral dose and of GLPG3067, GLPG2222, and GLPG2737 after multiple oral doses in healthy subjects

  2. Area under the plasma concentration-time curve of GLPG3067 (AUC0-t) given alone or in combination with GLPG2222 or in combination with GLPG2222 and GLPG2737 [ Time Frame: Between Day 1 predose and 10 days after the last dose ]
    To characterize pharmacokinetics of GLPG3067 after a single oral dose and of GLPG3067, GLPG2222, and GLPG2737 after multiple oral doses in healthy subjects

  3. Ratio of 4-beta-hydroxycholesterol/cholesterol in plasma after multiple oral doses in healthy subjects [ Time Frame: Day 1 predose and Day 14 ]
    To assess the potential for CYP3A4 interaction with GLPG3067, GLPG3067 and GLPG2222, or GLPG3067 and GLPG2222 and GLPG2737

  4. Maximum observed plasma concentration of GLPG3067 (Cmax) given alone in fed state [ Time Frame: Between Day 1 predose and 10 days after the last dose ]
    To assess the relative bioavailability of GLPG3067 when given as a single dose of oral suspension or an oral tablet both administered in fed state

  5. Concentration in plasma observed at 24 hours post dose (C24h) of GLPG3067 given alone in fed state [ Time Frame: Between Day 1 predose and 10 days after the last dose ]
    To assess the relative bioavailability of GLPG3067 when given as a single dose of oral suspension or an oral tablet both administered in fed state

  6. Area under the plasma concentration-time curve of GLPG3067 (AUC0-t) given alone in fed state [ Time Frame: Between Day 1 predose and 10 days after the last dose ]
    To assess the relative bioavailability of GLPG3067 when given as a single dose of oral suspension or an oral tablet both administered in fed state

  7. Maximum observed plasma concentration of GLPG3067 (Cmax) given alone in fasted state [ Time Frame: Between Day 1 predose and 10 days after the last dose ]
    To assess the effect of food on the pharmacokinetics of GLPG3067 when given under fasted versus fed conditions

  8. Concentration in plasma observed at 24 hours post dose (C24h) of GLPG3067 given alone in fasted state [ Time Frame: Between Day 1 predose and 10 days after the last dose ]
    To assess the effect of food on the pharmacokinetics of GLPG3067 when given under fasted versus fed conditions

  9. Area under the plasma concentration-time curve of GLPG3067 (AUC0-t) given alone in fasted state [ Time Frame: Between Day 1 predose and 10 days after the last dose ]
    To assess the effect of food on the pharmacokinetics of GLPG3067 when given under fasted versus fed conditions



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female subject between 18-70 years of age, inclusive, on the date of signing the informed consent form (ICF).
  • Be of non-childbearing potential defined as surgically sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy), or post-menopausal (at least 12 consecutive months without menstruation, without an alternative medical cause [including hormone replacement therapy]).
  • Have a body mass index between 18-30 kg/m2, inclusive.
  • Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead triplicate electrocardiogram (ECG), and clinical safety laboratory tests prior to the initial study drug administration.
  • Discontinuation of all medications (including over-the-counter and/or prescription medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements, and hormonal replacement therapy for postmenopausal subjects) except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) at least 2 weeks prior to the first study drug administration.

Exclusion Criteria:

  • Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
  • Clinically significant symptoms or illness in the 3 months before screening.
  • Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  • Any laboratory result considered by the investigator as clinically significant prior to study drug administration.
  • Creatinine clearance ≤80 mL/min using the Cockcroft-Gault formula for subjects aged ≤50 years, or creatinine clearance ≤70 mL/min using the Cockcroft-Gault formula for subjects aged >50 years. A 24-hour urine collection to determine the actual value may be performed to confirm creatinine clearance if required.
  • Clinically significant abnormalities of vital signs at screening.
  • Clinically relevant abnormalities detected on ECG regarding either rhythm or conduction (e.g. QT interval corrected for heart rate using Fridericia's formula [QTcF] >470 ms) or a known long QT syndrome. A first degree heart block or sinus arrhythmia will not be considered as a significant abnormality.
  • Participation in a drug, drug and device delivery system or combination, or biologic investigational research study within 8 weeks or 5 times the half-life of the investigational drug, if the half-life is known (whichever is longer) prior to initial study drug administration. Subjects who have been dosed previously with GLPG3067 in a clinical trial are allowed to participate Part 4 of this study as long as they completed their last follow-up visit or a washout period of 5 times the half-life of GLPG3067 (whichever is longer) after the last study drug administration is respected.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03128606


Locations
Layout table for location information
Belgium
SGS LSS Clinical Pharmacology Unit Antwerp
Antwerp, Belgium
Sponsors and Collaborators
Galapagos NV
Investigators
Layout table for investigator information
Study Director: Magdalena Petkova, MD Galapagos NV
Layout table for additonal information
Responsible Party: Galapagos NV
ClinicalTrials.gov Identifier: NCT03128606    
Other Study ID Numbers: GLPG3067-CL-101
First Posted: April 25, 2017    Key Record Dates
Last Update Posted: April 10, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No